← All trials
NCT05250596
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2022
- Primary completion
- Sep 24, 2022
- Completion date
- Dec 30, 2022
- First posted
- Feb 22, 2022
- Last posted
- Mar 16, 2022
- Enrollment
- 175
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Azienda USL 4 PratoLead sponsor
- Azienda USL 4 PratoReponsible party - principal investigator
- Azienda USL 4 PratoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.